Zevra Q2 revenue falls to $4.4M, net loss $19.9M; FDA decision on arimoclomol by Sept 21

ZEVRA THERAPEUTICS, INC.

2025-Q2 EPS reported -$0.87 vs consensus $1.53 ▼ miss (-156.9%)

Net revenue $4.4M vs $8.5M YoY; net loss $19.9M ($0.48/share) vs $2.6M ($0.08/share) in Q2 2023.
FDA advisory committee voted arimoclomol effective for NPC; PDUFA target action date Sept 21, 2024.
Pro-forma cash $113.8M after $64.5M net from August public offering; cash runway into Q1 2027.
OLPRUVA added 9 new patient enrollments in Q2; reimbursement coverage expanded to 75% of covered lives.
Refinanced debt with $100M credit facility from Perceptive Advisors and HCR; initial draw $60M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.